ProCE Banner Activity

CARISEL Interim Results: Acceptability, Appropriateness, Feasibility, Barriers, and Facilitators of LA CAB + RPV

Slideset Download
Conference Coverage
Participants found LA CAB + RPV to be an acceptable, appropriate, and feasible treatment option for maintenance of HIV virologic suppression from Months 1 to 4.

Released: November 02, 2021

Expiration: November 01, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.

ViiV Healthcare